Germans Trias i Pujol University Hospital, Centro de Investigación Biomédica en red en Enfermedades Hepatica y Digestivas, Badalona, Spain.
J Gastrointestin Liver Dis. 2011 Dec;20(4):355-8.
Skip inflammation of the appendiceal orifice has been described in distal UC (UC-IAO) but long-term clinical outcomes are poorly established. Our aim was to evaluate the long-term clinical outcomes of UC-IAO as compared to classic distal UC.
Patients with UC-IAO were identified from the local IBD database. Disease outcome and therapeutic requirements during follow-up were accurately collected, and compared with a control group of patients with distal UC without peri-appendiceal involvement matched by disease extent (proctitis/distal), smoking habit, and date and age at diagnosis.
Fourteen UC patients were found to have UC-IAO, most of them with initial extent of UC limited to the rectum. All patients were initially managed with mesalazine administered orally (28.5%), topically (28.5%), or in combination (43%). After a median follow-up of 78 months (interquartile range--IQR 45-123) most UC-IAO patients were successfully managed with oral and/or topical aminosalicylates. Only one of them developed proximal disease progression. As compared to controls, no differences in clinical outcomes or therapeutic requirements were found.
Patients with UC-IAO tend to present a mild course, with a low probability to develop proximal progression of disease extent or to require immunosuppressive therapy or colectomy.
末端回肠炎（UC-IAO）患者的阑尾口通常不存在炎症，但 UC-IAO 的长期临床结局尚不清楚。本研究旨在评估 UC-IAO 与经典远端 UC 相比的长期临床结局。
从当地 IBD 数据库中确定 UC-IAO 患者。准确收集随访期间的疾病结局和治疗需求，并与无阑尾周围累及的远端 UC 患者（通过疾病范围、吸烟习惯、诊断时的年龄和日期匹配）进行比较。
发现 14 例 UC 患者存在 UC-IAO，其中大多数患者初始 UC 局限于直肠。所有患者最初均接受口服（28.5%）、局部（28.5%）或联合治疗（43%）的美沙拉嗪治疗。中位随访 78 个月（四分位距 IQR 45-123）后，大多数 UC-IAO 患者经口服和/或局部氨基水杨酸盐治疗成功缓解。其中仅 1 例出现近端疾病进展。与对照组相比，UC-IAO 患者的临床结局和治疗需求无差异。
UC-IAO 患者的病程通常较轻，发生疾病范围近端进展、需要免疫抑制治疗或结肠切除术的可能性较低。
